Biolidics Statistics
Total Valuation
Biolidics has a market cap or net worth of SGD 7.75 million. The enterprise value is 8.87 million.
Market Cap | 7.75M |
Enterprise Value | 8.87M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Biolidics has 774.76 million shares outstanding. The number of shares has increased by 67.09% in one year.
Shares Outstanding | 774.76M |
Shares Change (YoY) | +67.09% |
Shares Change (QoQ) | -6.30% |
Owned by Insiders (%) | 35.93% |
Owned by Institutions (%) | 6.23% |
Float | 477.38M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.44 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.97 |
EV / Sales | 6.95 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17
Current Ratio | 0.17 |
Quick Ratio | 0.08 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -40.42 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -91.01% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | 85,067 |
Profits Per Employee | -199,000 |
Employee Count | 15 |
Asset Turnover | 0.63 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.57% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -28.57% |
50-Day Moving Average | 0.01 |
200-Day Moving Average | 0.01 |
Relative Strength Index (RSI) | 50.46 |
Average Volume (20 Days) | 1,435,015 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biolidics had revenue of SGD 1.28 million and -2.99 million in losses. Loss per share was -0.00.
Revenue | 1.28M |
Gross Profit | 566,000 |
Operating Income | -2.95M |
Pretax Income | -2.91M |
Net Income | -2.99M |
EBITDA | -2.94M |
EBIT | -2.95M |
Loss Per Share | -0.00 |
Balance Sheet
The company has 150,000 in cash and 1.27 million in debt, giving a net cash position of -1.12 million or -0.00 per share.
Cash & Cash Equivalents | 150,000 |
Total Debt | 1.27M |
Net Cash | -1.12M |
Net Cash Per Share | -0.00 |
Equity (Book Value) | -2.39M |
Book Value Per Share | -0.00 |
Working Capital | -2.27M |
Cash Flow
Operating Cash Flow | -1.34M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 44.36%, with operating and profit margins of -231.27% and -233.93%.
Gross Margin | 44.36% |
Operating Margin | -231.27% |
Pretax Margin | -228.21% |
Profit Margin | -233.93% |
EBITDA Margin | -230.64% |
EBIT Margin | -231.27% |
FCF Margin | n/a |
Dividends & Yields
Biolidics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -67.09% |
Shareholder Yield | -67.09% |
Earnings Yield | -43.06% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |